Shares of Agile Therapeutics Inc (NASDAQ:AGRX) have received a consensus recommendation of “Buy” from the eight research firms that are presently covering the company, MarketBeat reports. Three research analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $3.75.

A number of brokerages have weighed in on AGRX. Maxim Group began coverage on shares of Agile Therapeutics in a report on Thursday, November 29th. They set a “buy” rating and a $3.00 target price on the stock. HC Wainwright set a $4.00 target price on shares of Agile Therapeutics and gave the stock a “buy” rating in a report on Tuesday, October 9th.

Shares of NASDAQ:AGRX traded up $0.01 on Friday, reaching $0.80. 185,700 shares of the company’s stock were exchanged, compared to its average volume of 1,634,621. The stock has a market capitalization of $28.02 million, a price-to-earnings ratio of -0.88 and a beta of -0.95. Agile Therapeutics has a fifty-two week low of $0.23 and a fifty-two week high of $5.18.

Agile Therapeutics (NASDAQ:AGRX) last issued its earnings results on Thursday, November 1st. The specialty pharmaceutical company reported ($0.11) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.15) by $0.04. On average, sell-side analysts predict that Agile Therapeutics will post -0.59 earnings per share for the current fiscal year.

An institutional investor recently raised its position in Agile Therapeutics stock. Renaissance Technologies LLC grew its holdings in shares of Agile Therapeutics Inc (NASDAQ:AGRX) by 76.3% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 792,990 shares of the specialty pharmaceutical company’s stock after purchasing an additional 343,290 shares during the period. Renaissance Technologies LLC owned 2.31% of Agile Therapeutics worth $392,000 as of its most recent SEC filing. Institutional investors own 42.02% of the company’s stock.

Agile Therapeutics Company Profile

Agile Therapeutics, Inc, a women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch, which completed Phase III clinical trials.

Featured Story: What do investors mean by earnings per share?

Analyst Recommendations for Agile Therapeutics (NASDAQ:AGRX)

Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with's FREE daily email newsletter.